Suhail A. Ansari

机构：Helmholtz Munich, Deutsches Diabetes-Zentrum e.V., German Center for Diabetes Research, Heinrich Heine University Düsseldorf · ORCID：0000-0001-9418-8857

发表论文 22 篇 · 总被引 756 次 · h-index 10

代表论文

• Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer (2020 · Nature Communications · 被引 372)
• miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer (2016 · Scientific Reports · 被引 74)
• Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer (2018 · Clinical Cancer Research · 被引 67)
• The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer (2016 · Oncotarget · 被引 60)
• Anti-inflammatory glucocorticoid action: genomic insights and emerging concepts (2020 · Current Opinion in Pharmacology · 被引 46)
• Concurrent Proinflammatory and Apoptotic Activity of a Helicobacter pylori Protein (HP986) Points to Its Role in Chronic Persistence (2011 · PLoS ONE · 被引 38)